• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CTLA4 Gene Record

  • Summary
  • Interactions
  • Claims
  • CTLA4 1493 Druggable GenomeClinically Actionable

    Alternate Names:

    1493
    CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4
    CTLA4
    ALPS5
    CD
    CD152
    CELIAC3
    CTLA-4
    GRD4
    GSE
    IDDM12
    123890
    2505
    ENSG00000163599
    OTTHUMG00000132877
    PA27006
    P16410
    CD_antigen=CD152
    Cytotoxic T-lymphocyte protein 4
    Cytotoxic T-lymphocyte-associated antigen 4
    1285
    T15000

    Gene Info:

    CancerCommons Reported Gene Name Anti-CTLA4
    Target Class Receptors
    Target Subclass Miscellaneous
    Target Subclass CTLA4
    Gene Biotype PROTEIN_CODING
    (12 More Sources)

    Gene Categories: Category Details

    EXTERNAL SIDE OF PLASMA MEMBRANE
    DRUGGABLE GENOME
    CLINICALLY ACTIONABLE

    Publications:

    Yang et al., Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis., J. Immunother.
    Oki et al., 1999, Augmentation of CTLA-4 expression by wortmannin: involvement of lysosomal sorting properties of CTLA-4., Int. Immunol.
    Kasai et al., 1998, Blockade of CD28/B7 interaction suppresses allergic eosinophilic inflammation in mice., Int. Arch. Allergy Immunol.
    Okazaki et al., 2001, Impairment of bleomycin-induced lung fibrosis in CD28-deficient mice., J. Immunol.
    Lai et al., 1994, CD28 signaling causes a sustained down-regulation of I kappa B alpha which can be prevented by the immunosuppressant rapamycin., J. Biol. Chem.
    Vanasek et al., 2001, Antagonistic roles for CTLA-4 and the mammalian target of rapamycin in the regulation of clonal anergy: enhanced cell cycle progression promotes recall antigen responsiveness., J. Immunol.
    Laso et al., 2000, Alcoholic liver cirrhosis is associated with a decreased expression of the CD28 costimulatory molecule, a lower ability of T cells to bind exogenous IL-2, and increased soluble CD8 levels., Cytometry
    Kusztal M et al., 2007, Possible association of CTLA-4 gene polymorphism with cyclosporine-induced gingival overgrowth in kidney transplant recipients., Transplant Proc
    Umland et al., 1999, Effects of cyclosporin A and dinactin on T-cell proliferation, interleukin-5 production, and murine pulmonary inflammation., Am. J. Respir. Cell Mol. Biol.
    Favis R et al., 2011, Genetic variation associated with bortezomib-induced peripheral neuropathy., Pharmacogenet Genomics
    Bossowski et al., 2004, [Analysis of costimulatory molecules (CD28-CTLA-4/B7) expression on chosen mononuclear cells in adolescents with Graves' disease during methimazole therapy]., Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw
    Juffermans et al., 2000, Thalidomide suppresses Up-regulation of human immunodeficiency virus coreceptors CXCR4 and CCR5 on CD4+ T cells in humans., J. Infect. Dis.
    Herbst et al., 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients., Nature
  • TREMELIMUMAB   CTLA4

    Interaction Score: 17.17

    Interaction Types & Directionality:
    antibody (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Trial Name Tremelimumab
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ChemblInteractions TTD

  • IPILIMUMAB   CTLA4

    Interaction Score: 5.5

    Interaction Types & Directionality:
    antibody (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Ipilimumab
    Novel drug target Established target
    Notes

    PMIDs:
    18049334


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions CancerCommons TTD

  • ZALIFRELIMAB   CTLA4

    Interaction Score: 3.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • ABATACEPT   CTLA4

    Interaction Score: 2.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9758890


    Sources:
    NCI

  • ANTIBIOTIC   CTLA4

    Interaction Score: 0.69

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10030847


    Sources:
    NCI

  • ATEZOLIZUMAB   CTLA4

    Interaction Score: 0.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25428504


    Sources:
    CIViC

  • METHIMAZOLE   CTLA4

    Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15504312


    Sources:
    NCI

  • MELPHALAN   CTLA4

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21228734


    Sources:
    PharmGKB

  • BLEOMYCIN   CTLA4

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11489978


    Sources:
    NCI

  • WORTMANNIN   CTLA4

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10464177


    Sources:
    NCI

  • PREDNISONE   CTLA4

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21228734


    Sources:
    PharmGKB

  • THALIDOMIDE   CTLA4

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10823791


    Sources:
    NCI

  • SIROLIMUS   CTLA4

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7982907 11698435


    Sources:
    NCI

  • CYCLOSPORINE   CTLA4

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18021981


    Sources:
    PharmGKB

  • TACROLIMUS   CTLA4

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DEXAMETHASONE   CTLA4

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21228734


    Sources:
    PharmGKB

  • ALCOHOL   CTLA4

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11025487


    Sources:
    NCI

  • BORTEZOMIB   CTLA4

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21228734


    Sources:
    PharmGKB

  • Ensembl: ENSG00000163599

    • Version: 101_38

    Alternate Names:
    CTLA4 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TdgClinicalTrial: P16410

    • Version: January-2014

    Alternate Names:
    CTLA4 Gene Symbol

    Gene Info:
    Target Class Receptors
    Target Subclass Miscellaneous
    Target Subclass CTLA4

    Publications:

  • CancerCommons: CTLA4

    • Version: 25-July-2013

    Alternate Names:
    1493 Entrez Gene ID

    Gene Info:
    CancerCommons Reported Gene Name Anti-CTLA4

    Publications:

  • PharmGKB: CTLA4

    • Version: 18-August-2020

    Alternate Names:
    PA27006 PharmGKB ID

    Gene Info:

    Publications:
    Favis R et al., 2011, Genetic variation associated with bortezomib-induced peripheral neuropathy., Pharmacogenet Genomics
    Ferreira Vasconcelos LM et al., 2018, Polymorphism of IL10, IL4, CTLA4, and DAO Genes in Cross-Reactive Nonsteroidal Anti-inflammatory Drug Hypersensitivity., J Clin Pharmacol
    Cabaleiro T et al., 2016, Paradoxical psoriasiform reactions to anti-TNFα drugs are associated with genetic polymorphisms in patients with psoriasis., Pharmacogenomics J

  • CIViC: CTLA4

    • Version: 14-September-2020

    Alternate Names:
    1493 Entrez Gene ID
    1285 CIViC Gene ID

    Gene Info:

    Publications:
    Herbst et al., 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients., Nature

  • NCI: CTLA4

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Kasai et al., 1998, Blockade of CD28/B7 interaction suppresses allergic eosinophilic inflammation in mice., Int. Arch. Allergy Immunol.
    Okazaki et al., 2001, Impairment of bleomycin-induced lung fibrosis in CD28-deficient mice., J. Immunol.
    Umland et al., 1999, Effects of cyclosporin A and dinactin on T-cell proliferation, interleukin-5 production, and murine pulmonary inflammation., Am. J. Respir. Cell Mol. Biol.

  • HingoraniCasas: ENSG00000163599

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000163599 Gene Symbol
    CTLA4 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • MyCancerGenome: CTLA4

    • Version: 20-Jun-2017

    Alternate Names:
    1493 Entrez Gene Id
    CTLA4 MyCancerGenome Gene Symbol
    CTLA4 MyCancerGenome Reported Gene Name

    Gene Info:

    Publications:

  • ChemblInteractions: CD152

    • Version: chembl_23

    Alternate Names:
    CD152 GENE_SYMBOL
    CTLA4 GENE_SYMBOL
    Cytotoxic T-lymphocyte protein 4 UNIPROT

    Gene Info:

    Publications:

  • TALC: CTLA-4

    • Version: 12-May-2016

    Alternate Names:
    CTLA-4 Gene Symbol

    Gene Info:

    Publications:

  • GO: CTLA4

    • Version: 01-February-2022

    Alternate Names:
    CD152 GO Gene Synonym

    Gene Info:

    Gene Categories:
    EXTERNAL SIDE OF PLASMA MEMBRANE

    Publications:

  • Tempus: CTLA4

    • Version: 11-November-2018

    Alternate Names:
    CTLA4 Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • TTD: Cytotoxic T-lymphocyte protein 4

    • Version: 2020.06.01

    Alternate Names:
    CTLA-4 TTD Gene Abbreviation
    T15000 TTD Target ID

    Gene Info:

    Publications:

  • MskImpact: CTLA4

    • Version: May-2015

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • ClearityFoundationClinicalTrial: CTLA-4

    • Version: 15-June-2013

    Alternate Names:

    Gene Info:

    Publications:

  • CarisMolecularIntelligence: CTLA4

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21